Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All casirivimab/imdevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

Somersan-Karakaya et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiac320 (date from preprint), NCT04426695
Nov 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 36% Improvement Relative Risk Mortality (b) 56% Mortality (c) 21% Death/intubation 31% Discharge 30% Casirivimab/i..  Somersan-Karakaya et al.  LATE TREATMENT  DB RCT Is late treatment with casirivimab/imdevimab beneficial for COVID-19? Double-blind RCT 1,197 patients in multiple countries (Jun 2020 - Apr 2021) Lower mortality (p=0.021) and death/intubation (p=0.027) c19early.org Somersan-Karakaya et al., The J. Infec.., Nov 2021 Favorscasirivimab/im.. Favorscontrol 0 0.5 1 1.5 2+
17th treatment shown to reduce risk in March 2021
 
*, now with p = 0.000055 from 29 studies, recognized in 45 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
RCT 1,336 hospitalized patients with symptom onset <=10 days on low-flow or no supplemental oxygen, showing lower mortality with treatment. Cohorts 2&3 were paused mid-trial due to increased deaths in the treatment arm and these results were not included.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants1-6.
risk of death, 35.9% lower, RR 0.64, p = 0.02, treatment 59 of 804 (7.3%), control 45 of 393 (11.5%), NNT 24, day 28, mFAS.
risk of death, 55.6% lower, RR 0.44, p = 0.005, treatment 24 of 360 (6.7%), control 24 of 160 (15.0%), NNT 12, seronegative, day 28, mFAS.
risk of death, 21.3% lower, RR 0.79, p = 0.42, treatment 26 of 369 (7.0%), control 18 of 201 (9.0%), NNT 52, seropositive, day 28, mFAS.
risk of death/intubation, 30.9% lower, RR 0.69, p = 0.03, treatment 82 of 804 (10.2%), control 58 of 393 (14.8%), NNT 22, day 1-29, mFAS.
risk of no hospital discharge, 30.2% lower, RR 0.70, p = 0.02, treatment 90 of 804 (11.2%), control 63 of 393 (16.0%), NNT 21, day 1-29, mFAS.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Conflicts of interest: research funding from the drug patent holder, employee of the drug patent holder.
Somersan-Karakaya et al., 8 Nov 2021, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, median age 62.0, 34 authors, study period 10 June, 2020 - 9 April, 2021, average treatment delay 6.0 days, trial NCT04426695 (history).
This PaperCasirivimab/i..All
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
MD Selin Somersan-Karakaya, MD Eleftherios Mylonakis, MD Vidya P Menon, MD Jason C Wells, PharmD Shazia Ali, MD Sumathi Sivapalasingam, PhD Yiping Sun, PhD Rafia Bhore, PhD Jingning Mei, BS, RN Jutta Miller, PhD Lisa Cupelli, MD Eduardo Forleo-Neto, PhD Andrea T Hooper, PhD Jennifer D Hamilton, Cynthia Pan, BS Viet Pham, MS Yuming Zhao, MD, MPH Romana Hosain, MD Adnan Mahmood, PhD John D Davis, PhD Kenneth C Turner, PharmD Yunji Kim, BS, Dip.Reg Amanda Cook, Aff, MS Bari Kowal, PhD Yuhwen Soo, PhD A Thomas Dicioccio, MD Gregory P Geba, Dr Ph, PhD Neil Stahl, PhD Leah Lipsich, MD Ned Braunstein, MD Gary A Herman, MD, PhD George D Yancopoulos, MD David M Weinreich
doi:10.1093/infdis/jiac320/6650790
Background: The open-label RECOVERY study reported improved survival in hospitalized, SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS+IMD). Methods: In this phase I/II/III, double-blind, placebo-controlled trial conducted prior to widespread circulation of Delta and Omicron, hospitalized COVID-19 patients were randomized (1:1:1) to 2.4 g or 8.0 g CAS+IMD or placebo, and characterized at baseline for viral load and SARS-CoV-2 serostatus. Results: 1336 patients on low-flow or no supplemental (low-flow/no) oxygen were treated. The primary endpoint was met: in seronegative patients, the least-squares mean difference (CAS+IMD versus placebo) for time-weighted average change from baseline in viral load through day 7 was -0.28 log 10 copies/mL (95% CI, -0.51 to -0.05; P=.0172). The primary clinical analysis of death or mechanical ventilation (death/MV) from day 6-29 in patients with high viral load had a strong positive trend but did not reach significance. CAS+IMD numerically reduced all-cause mortality in seronegative patients through day 29 (relative risk reduction, 55.6%; 95% CI, 24.2-74.0). No safety concerns were noted. Conclusions: In hospitalized COVID-19 patients on low-flow/no oxygen, CAS+IMD reduced viral load and likely improves clinical outcomes in the overall population, with the benefit driven by seronegative patients, and no harm observed in seropositive patients.
Notes Forest plot shows relative risk and relative risk reduction with 95% CIs for CAS+IMD combined dose analysis (2.4 g and 8.0 g) versus placebo. Parameters examined include death within 28 days, discharge alive from hospital from days 1 to 29, and death or mechanical ventilation from days 1 to 29. For all populations, the mFAS was comprised of patients who tested positive for SARS-CoV-2 at baseline. Populations analyzed include patients who tested negative for all SARS-CoV-2 antibodies at baseline (seronegative mFAS), patients who tested positive for any SARS-CoV-2 antibody at baseline (seropositive mFAS), those with borderline, inconclusive or missing baseline serology (other), and the overall population regardless of serostatus (overall mFAS). For the proportion of death within 28 days and the proportion of death or mechanical ventilation with 28 days, the lower bounds of the CI of the relative risk reduction were -342.0% and -241.0%, respectively, which are presented as "NA" in the figure . Abbreviations: CAS+IMD, casirivimab and imdevimab; CI, confidence interval; mFAS, modified full analysis set; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
References
Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science
Copin, Baum, Wloga, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Cell
Goyal, Choi, Pinheiro, Clinical characteristics of Covid-19 in New York City, N Engl J Med
Group, Lundgren, Grund, A neutralizing monoclonal antibody for hospitalized patients with Covid-19, N Engl J Med
Group, Lundgren, Grund, Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19, medRxiv
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hansen, Baum, Pascal, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science
Horby, Lim, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial, JAMA
Marconi, Ramanan, De Bono, Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial, Lancet Respir Med
O'brien, Forleo-Neto, Musser, Subcutaneous REGEN-COV antibody combination for Covid-19 prevention, medRxiv
O'brien, Forleo-Neto, Musser, Subcutaneous REGEN-COV antibody combination to prevent Covid-19, N Engl J Med
Plains, Center, Plains, Ny, Schelker et al., Former employee of Regeneron Pharmaceuticals
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Rosas, Brau, Waters, Tocilizumab in hospitalized patients with severe Covid-19 pneumonia, N Engl J Med
Sharun, Tiwari, Dhama, Emran, Rabaan et al., Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies, Hum Vaccin Immunother
Verderese, Stepanova, Lam, Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19: A real-world experience, Clin Infect Dis
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
{ 'indexed': {'date-parts': [[2022, 7, 27]], 'date-time': '2022-07-27T17:41:30Z', 'timestamp': 1658943690399}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2022, 7, 27]], 'date-time': '2022-07-27T00:00:00Z', 'timestamp': 1658880000000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>The open-label RECOVERY study reported improved survival in ' 'hospitalized, SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab ' '(CAS\u2009+\u2009IMD).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>In this phase I/II/III, double-blind, placebo-controlled trial ' 'conducted prior to widespread circulation of Delta and Omicron, hospitalized COVID-19 ' 'patients were randomized (1:1:1) to 2.4\u2005g or 8.0\u2005g CAS\u2009+\u2009IMD or placebo, ' 'and characterized at baseline for viral load and SARS-CoV-2 serostatus.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>1336 patients on low-flow or no supplemental (low-flow/no) oxygen ' 'were treated. The primary endpoint was met: in seronegative patients, the least-squares mean ' 'difference (CAS\u2009+\u2009IMD versus placebo) for time-weighted average change from ' 'baseline in viral load through day 7 was –0.28 log10 copies/mL (95% CI, –0.51 to –0.05; ' 'P\u2009=\u2009.0172). The primary clinical analysis of death or mechanical ventilation ' '(death/MV) from day 6–29 in patients with high viral load had a strong positive trend but did ' 'not reach significance. CAS\u2009+\u2009IMD numerically reduced all-cause mortality in ' 'seronegative patients through day 29 (relative risk reduction, 55.6%; 95% CI, 24.2–74.0). No ' 'safety concerns were noted.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>In hospitalized COVID-19 patients on low-flow/no oxygen, CAS\u2009' '+\u2009IMD reduced viral load and likely improves clinical outcomes in the overall ' 'population, with the benefit driven by seronegative patients, and no harm observed in ' 'seropositive patients.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/infdis/jiac320', 'type': 'journal-article', 'created': {'date-parts': [[2022, 7, 27]], 'date-time': '2022-07-27T16:59:39Z', 'timestamp': 1658941179000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19', 'prefix': '10.1093', 'author': [ { 'given': 'Selin', 'family': 'Somersan-Karakaya', 'sequence': 'first', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Eleftherios', 'family': 'Mylonakis', 'sequence': 'additional', 'affiliation': [{'name': 'Brown University , Providence, RI , USA'}]}, { 'given': 'Vidya P', 'family': 'Menon', 'sequence': 'additional', 'affiliation': [{'name': 'NYC Health + Hospitals/Lincoln, \xa0 The Bronx, NY , USA'}]}, { 'given': 'Jason C', 'family': 'Wells', 'sequence': 'additional', 'affiliation': [ {'name': 'The Oregon Clinic , Portland, OR , USA'}, {'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Shazia', 'family': 'Ali', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Sumathi', 'family': 'Sivapalasingam', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Yiping', 'family': 'Sun', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Rafia', 'family': 'Bhore', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Jingning', 'family': 'Mei', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Jutta', 'family': 'Miller', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Lisa', 'family': 'Cupelli', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Eduardo', 'family': 'Forleo-Neto', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Andrea T', 'family': 'Hooper', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Jennifer D', 'family': 'Hamilton', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Cynthia', 'family': 'Pan', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Viet', 'family': 'Pham', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Yuming', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Romana', 'family': 'Hosain', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Adnan', 'family': 'Mahmood', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'John D', 'family': 'Davis', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Kenneth C', 'family': 'Turner', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Yunji', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Amanda', 'family': 'Cook', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Bari', 'family': 'Kowal', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Yuhwen', 'family': 'Soo', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'A Thomas', 'family': 'DiCioccio', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Gregory P', 'family': 'Geba', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Neil', 'family': 'Stahl', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Leah', 'family': 'Lipsich', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Ned', 'family': 'Braunstein', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'Gary A', 'family': 'Herman', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'George D', 'family': 'Yancopoulos', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'given': 'David M', 'family': 'Weinreich', 'sequence': 'additional', 'affiliation': [{'name': 'Regeneron Pharmaceuticals, Inc. , Tarrytown, NY , USA'}]}, { 'name': 'for the COVID-19 Phase 2/3 Hospitalized Trial Team', 'sequence': 'additional', 'affiliation': []}], 'member': '286', 'published-online': {'date-parts': [[2022, 7, 27]]}, 'container-title': 'The Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiac320/45108752/jiac320.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiac320/45108752/jiac320.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 7, 27]], 'date-time': '2022-07-27T16:59:39Z', 'timestamp': 1658941179000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac320/6650790'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7, 27]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/infdis/jiac320', 'relation': {}, 'ISSN': ['0022-1899', '1537-6613'], 'subject': ['Infectious Diseases', 'Immunology and Allergy'], 'published': {'date-parts': [[2022, 7, 27]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit